Difelikefalin
Brand names: Korsuva ยท Active ingredient: Difelikefalin Acetate
In short: KORSUVA is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Limitations of Use KORSUVA has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.
What is Difelikefalin used for?
KORSUVA is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).
Limitations of Use
KORSUVA has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.
Difelikefalin dosage
The recommended dosage of KORSUVA is 0.5 mcg/kg administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each HD treatment .
If a regularly scheduled HD treatment is missed, resume KORSUVA at the end of the next HD treatment.
Do not mix or dilute KORSUVA prior to administration.
Inspect KORSUVA for particulate matter and discoloration prior to administration. The solution should be clear and colorless. Do not use KORSUVA vials if particulate matter or discoloration is observed.
KORSUVA is supplied in a single-dose vial. Discard any unused product.
Injection volume to be administered is determined by patient's target dry body weight in kilograms (one patient may use less than the full contents of the vial or use more than one vial). See Table 1.
Target Dry Body Weight Range (kg) | Injection Volume (mL)Total Injection Volume (mL) = Patient Target Dry Body Weight (kg) x 0.01, rounded to the nearest tenth (0.1 mL). For patient target dry body weight outside of the ranges in Table 1, use this formula.
36 โ 44 | 0.4
45 โ 54 | 0.5
55 โ 64 | 0.6
65 โ 74 | 0.7
75 โ 84 | 0.8
85 โ 94 | 0.9
95 โ 104 | 1
105 โ 114 | 1.1
115 โ 124 | 1.2
125 โ 134 | 1.3
135 โ 144 | 1.4
145 โ 154 | 1.5
155 โ 164 | 1.6
165 โ 174 | 1.7
175 โ 184 | 1.8
185 โ 194 | 1.9
195 โ 204 | 2
KORSUVA is removed by the dialyzer membrane and must be administered after blood is no longer circulating through the dialyzer.
Administer KORSUVA by intravenous bolus injection into the venous line of the dialysis circuit at the end of each HD session.
The dose may be given either during or after rinse back of the dialysis circuit.
If the dose is given after rinse back, administer KORSUVA into the venous line followed by at least 10 mL of normal saline flush.
If the dose is given during rinse back, no additional normal saline is needed to flush the line.
The dose must be administered within 4 hours of the syringe preparation. Discard any unused product.
How to take Difelikefalin โ instructions & advice from the label
Dizziness, Somnolence, Mental Status Changes, and Gait Disturbances
Inform patients that dizziness, somnolence, mental status changes, and gait disturbances, including falls, can occur during treatment with KORSUVA . Somnolence is more likely to happen to patients who are age 65 years or older.
Inform patients that concomitant treatment with centrally-acting depressants, sedating antihistamines and opioid analgesics may increase the likelihood of these adverse reactions and these medications should be used with caution during treatment with KORSUVA .
Driving or Operating Machinery
Inform patients that KORSUVA may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Advise patients not to drive or operate machinery until they know how they will react to KORSUVA .
Warnings & precautions
Do not take this medicine if: None
Dizziness, somnolence, mental status changes, and gait disturbances, including falls, have occurred in patients taking KORSUVA and may subside over time with continued treatment . In Trial 1 and Trial 2, 17.0% of patients randomized to receive KORSUVA reported at least one of these adverse reactions, compared to 12.0% of patients who received placebo. The incidence of somnolence was higher in KORSUVA-treated subjects 65 years of age and older (7.0%) than in KORSUVA-treated subjects less than 65 years of age (2.8%). Concomitant use of centrally-acting depressant medications, sedating antihistamines and opioid analgesics may increase the likelihood of these adverse reactions and should be used with caution during treatment with KORSUVA.
Dizziness, somnolence, and mental status changes have occurred in patients taking KORSUVA. KORSUVA may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. Advise patients not to drive or operate dangerous machinery until the effect of KORSUVA on a patient's ability to drive or operate machinery is known.
Difelikefalin side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Dizziness, Somnolence, Mental Status Changes, and Gait Disturbances
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
A total of 1306 subjects undergoing HD who had moderate-to-severe pruritus were treated with KORSUVA in placebo-controlled and uncontrolled Phase 3 clinical trials. Of these, 711 were treated for at least 6 months and 400 were treated for at least one year.
Two placebo-controlled Phase 3 trials (Trial 1 and Trial 2), in subjects undergoing HD who had moderate-to-severe pruritus were pooled to evaluate the safety of KORSUVA in comparison to placebo up to 12 weeks. In total, 848 subjects were evaluated (424 in KORSUVA group and 424 in placebo group). The mean age of the subjects was 59 years (range 22 to 88 years), and 59% of the subjects were male. Of the total subjects, 61% were White, 29% were Black or African American, and 5% were Asian.
Table 2 summarizes the adverse reactions that occurred at a rate of โฅ2% in the KORSUVA group and โฅ1% higher than that of the placebo group during the 12-week placebo-controlled period of Trials 1 and 2. โฆ
About this medicine
KORSUVA (difelikefalin) is a kappa opioid receptor agonist. Difelikefalin is a synthetic peptide with a single stereoisomer and is present as an acetate salt. Difelikefalin acetate is a white to off-white powder with a molecular formula of C36H53N7O6โxAcOH (1.0โค ร โค2.0) and a molecular weight of 679.4 g/mol (mono- isotopic; free base). It is soluble in water. The chemical name of difelikefalin acetate is 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid, acetate salt.
The chemical structure is:
KORSUVA (difelikefalin) injection is supplied in a single-dose vial containing 65 mcg/1.3 mL (50 mcg/mL) of difelikefalin as a sterile, preservative-free, clear and colorless solution for intravenous injection.
KORSUVA is formulated as an isotonic 40 mM acetate buffer solution with an osmolality of 250 to 350 mOsm and a pH of 4.5. โฆ
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0c7b81f2-0fd3-47cb-8b0f-185e07f19c87. Read the full official label on DailyMed.